Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | viral clearance | |||
| 2-deoxy-D-glucose (2-DG) | 0 | - | - | - | - | |
| acetylcysteine | 0 | - | - | - | - | |
| alpha lipoic acid | 0 | - | - | - | - | |
| anti-CK2 | 0 | - | - | - | - | |
| Aspirin | 0 | - | - | - | - | |
| aviptadil | 0 | - | - | - | - | |
| BLD-2660 (calpain inhibitor) | 0 | - | - | - | - | |
| calcium channel blocker | 0 | - | - | - | - | |
| camostat mesilate | 0 | - | - | - | - | |
| Cannabidiol | 0 | - | - | - | - | |
| continuous positive airway pressure (CPAP) | 0 | - | - | - | - | |
| cytokine adsorption | 0 | - | - | - | - | |
| diammonium glycyrrhizinate | 0 | - | - | - | - | |
| dipyridamol | 0 | - | - | - | - | |
| dornase alfa | 0 | - | - | - | - | |
| expectorants and mucolytics | 0 | - | - | - | - | |
| honey | 0 | - | - | - | - | |
| kinin-kallikrein inhibitors | 0 | - | - | - | - | |
| melatonin | 0 | - | - | - | - | |
| mouthrise and gargling agents | 0 | - | - | - | - | |
| N-Acetylcysteine | 0 | - | - | - | - | |
| nasal spray | 0 | - | - | - | - | |
| natural killer (NK) cells | 0 | - | - | - | - | |
| nicotin | 0 | - | - | - | - | |
| nigella sativa oil | 0 | - | - | - | - | |
| nitric oxide (gas Inhalation or releasing solution) | 0 | - | - | - | - | |
| omega-3 Polyunsaturated Fatty Acids | 0 | - | - | - | - | |
| ozonated autohemotherapy | 0 | - | - | - | - | |
| plasma exchange | 0 | - | - | - | - | |
| povidone-iodine | 0 | - | - | - | - | |
| previfenon (EGCG) | 0 | - | - | - | - | |
| prostacyclin | 0 | - | - | - | - | |
| PUL-042 inhalation solution | 0 | - | - | - | - | |
| pyridostigmine | 0 | - | - | - | - | |
| radiotherapy | 0 | - | - | - | - | |
| sabizabulin | 0 | - | - | - | - | |
| sildenafil | 0 | - | - | - | - | |
| triiodothyronine (T3) | 0 | - | - | - | - | |